Verastem, Inc.
VSTM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001526119
In the last 90 days, Verastem, Inc. insiders filed 0 open-market purchases and 4 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $363.5M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:51 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $209.5M (677.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Jan 13, 2025 | – | Feb 2, 2023 | Mar 28, 2022 |
| Revenue | $30.9M | $10.0M | – | $2.60M | $2.05M |
| Research and development | $114.6M | $81.3M | $61.4M | $50.6M | $39.3M |
| Selling, general and administrative | $81.1M | $43.6M | $30.7M | $25.0M | $24.1M |
| Operating income | -$170.1M | -$115.0M | -$92.1M | -$72.9M | -$61.4M |
| Interest expense | $1.14M | $4.56M | $4.14M | $2.14M | $9.97M |
| Income tax | – | $185.0K | – | $0 | $0 |
| Net income | -$209.5M | -$130.6M | -$87.4M | -$73.8M | -$71.2M |
| EPS, basic | $-3.02 | $-3.66 | $-3.96 | $-0.38 | $-0.41 |
| EPS, diluted | $-3.02 | $-3.66 | $-3.93 | $-0.38 | $-0.41 |
| Weighted shares, basic | 69.3M | 35.7M | 22.1M | 193.7M | 174.4M |
| Weighted shares, diluted | 69.3M | 35.7M | 22.1M | 193.7K | 174.4M |
| Margins and growth | |||||
| Operating margin | -550.3% | -1149.6% | – | -2809.6% | -2991.2% |
| Net margin | -677.6% | -1306.4% | – | -2843.3% | -3468.1% |
| Revenue growth, year over year | +209.1% | – | – | +26.4% | −97.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023! | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Jan 13, 2025 | – | Feb 2, 2023 | Mar 28, 2022 |
| Cash and equivalents | $205.0M | $88.8M | $77.9M | $74.9M | $21.3M |
| Inventory | $1.83M | – | – | – | – |
| Total current assets | $223.4M | $95.0M | $143.7M | $92.9M | $105.7M |
| Property, plant and equipment | – | $32.0K | $37.0K | $92.0K | $210.0K |
| Intangible assets | $16.4M | – | – | – | – |
| Total assets | $246.4M | $101.5M | $149.7M | $95.0M | $108.7M |
| Accounts payable | $12.4M | $4.03M | $7.18M | $4.90M | $2.30M |
| Total current liabilities | $72.3M | $31.0M | $26.4M | $21.7M | $18.6M |
| Long-term debt | – | $40.7M | $40.1M | $24.5M | – |
| Total liabilities | $189.2M | $130.4M | $71.2M | $47.7M | $21.1M |
| Shareholders' equity | $57.2M | -$28.9M | $57.4M | $47.4M | $87.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Jan 13, 2025 | – | Feb 2, 2023 | Mar 28, 2022 |
| Operating cash flow | -$137.5M | -$104.8M | -$86.5M | -$63.7M | -$53.5M |
| Capital expenditures | – | $28.0K | – | – | $196.0K |
| Free cash flow | – | -$104.8M | – | – | -$53.7M |
| Stock-based compensation | $9.40M | $7.34M | $5.86M | $6.05M | $7.71M |
| Investing cash flow | -$9.62M | $60.0M | -$44.4M | $66.2M | $87.0K |
| Financing cash flow | $263.3M | $54.8M | $134.2M | $51.8M | $6.88M |
| Net change in cash | $116.2M | $9.98M | $3.29M | $54.3M | -$46.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 30.4% | 73.4% | – | 232.9% | 375.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 126.0M | +88.7% | SEC |
| Aug 3, 2026 | 90.6M | +47.1% | SEC |
| May 4, 2026 | 87.9M | +59.9% | SEC |
| Feb 27, 2026 | 87.8M | +70.6% | SEC |
| Nov 3, 2025 | 66.8M | +50.0% | SEC |
| Aug 7, 2025 | 61.5M | +52.9% | SEC |
| May 12, 2025 | 54.9M | +117.0% | SEC |
| Mar 19, 2025 | 51.5M | +103.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-12 in Q2 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.